community
Adze Biotechnology — Oak Park, Illinois
Adze specializes in oncolytic immunotherapy: a type of cancer treatment that creates targeted immune evasion viruses that block proteins to tumors and kill cancer cells. Adze’s oncolytic vectors kill cancer cells directly by exposing cancer antigens to the immune system while stimulating the person’s immune response. The company’s technology hopes to add…
Read more
community
Every day, innovators across the MATTER community are building new solutions that accelerate innovation, advance care and improve lives. Here’s a look into the most noteworthy headlines from September.
Catalia Health teams up with Pfizer to pilot patient engagement robot
Catalia Health and Pfizer have launched a one year pilot study to explore how patients engage with artificial intelligence …
Read more
community
Our newest MATTER members are making it easier to manage food allergies, helping health systems create meaningful relationships with their patients, treating antibiotic-resistant infections and building a support structure for people recovering from substance abuse.
Alerje
Alerje aims to improve the quality of life for people living with food allergies by redefining how they manage them. With…
Read more
community
If you’ve spent time in the MATTER space, you’ve probably rubbed elbows with Michael Williams: A Brit by birth and seasoned healthcare innovator who, most recently, worked as a MATTER startup member. Now, Michael is putting his expertise to work as MATTER’s newest venture acceleration director.
Michael has experienced healthcare from nearly every angle — he’s led innovation in health systems, …
Read more
community
Every day, innovators across the MATTER community are building new solutions that accelerate innovation, advance care and improve lives. Here’s a look into the most noteworthy headlines from August.
Level Ex wins funding to save lives on Mars — yes, that Mars
Level Ex received a year-long grant to build a virtual simulation that trains astronauts for deep space travel. The company will work w…
Read more